Skip to main content

Table 3 Subgroup analysis of studies from China and outside China

From: Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis

Variable China Outside China p-value for interaction
Number of studies/patients Prevalence (95% CI) p-value (Cochran’s Q); I2 Number of studies/patients Prevalence (95% CI) p-value (Cochran’s Q); I2
Death 16/2035 0.15 (0.05–0.26) 0.00; 96% 14/10025 0.11 (0.03–0.20) 0.00; 98% 0.56
≥1 comorbidity 6/410 0.68 (0.53–0.82) 0.00; 85% 6/1478 0.84 (0.72–0.95) 0.00; 91% 0.09
Hypertension 11/1387 0.42 (0.28–0.57) 0.00; 91% 6/858 0.57 (0.39–0.74); 0.00; 81% 0.20
Diabetes Mellitus 10/921 0.22 (0.10–0.36); 0.00; 90% 7/883 0.22 (0.12–0.33) 0.01; 65% 1.00
Cardiovascular disease 9/901 0.14 (0.08–0.20) 0.00; 72% 4/778 0.26 (0.11–0.43) 0.00; 79% 0.17
Chronic Lung disease 9/883 0.07 (0.04–0.11) 0.02; 56% 6/865 0.08 (0.00–0.26) 0.00; 91% 0.88
Malignancy 7/702 0.05 (0.03–0.07) 0.30; 17% 5/774 0.13 (0.01–0.28) 0.00; 78% 0.25
Kidney disease 8/720 0.04 (0.01–0.07) 0.06; 48% 6/871 0.06 (0.00–0.18) 0.00; 87% 0.68
Liver disease 6/582 0.02 (0.00–0.06) 0.02; 62% 5/834 0.04 (0.01–0.07) 0.09; 50% 0.85
Fever 6/583 0.85 (0.56–1.00) 0.00; 95% 5/199 0.77 (0.67–0.87) 0.08; 58% 0.42
Cough 6/583 0.57 (0.47–0.67) 0.03; 61% 5/199 0.71 (0.61–0.81) 0.11; 12.47% 0.05
Dyspnoea 6/583 0.36 (0.07–0.68) 0.00; 95% 5/199 0.63 (0.45–0.80) 0.00; 78% 0.13